---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-019665"
form_type: "8-K"
ticker: "NUVL"
cik: "0001861560"
company_name: "Nuvalent, Inc."
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T19:26:00.361049+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nuvalent reports Q1 net loss $17.5M; cash $272.7M; ALK trial expected Q2 2022

## Summary
- Net loss of $17.5M ($0.36 diluted EPS); R&D expenses $12.7M, G&A $5.0M.
- Cash, cash equivalents and marketable securities of $272.7M; expected to fund operations into 2024.
- IND for NVL-655 (ALK) cleared; ALKOVE-1 Phase 1/2 trial anticipated to begin Q2 2022.
- On track to select two additional development candidates in 2022 (ALK resistance mutations and HER2 exon 20).
- Appointed Anna Protopapas as Chair of Board of Directors in March 2022.

## SEC filing metadata
- accession: 0001564590-22-019665
- form_type: 8-K
- ticker: NUVL
- cik: 0001861560
- company_name: Nuvalent, Inc.
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1861560/000156459022019665/0001564590-22-019665-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1861560/000156459022019665/nuvl-8k_20220512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-019665
- JSON: https://secwatch.observer/filing/0001564590-22-019665.json
- Plain text: https://secwatch.observer/filing/0001564590-22-019665.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.